A Multinational Pharmacoeconomic Evaluation of Acute Major Depressive Disorder (MDD): a Comparison of Cost-Effectiveness Between Venlafaxine, SSRIs and TCAs
- 1 January 2001
- journal article
- research article
- Published by Elsevier in Value in Health
- Vol. 4 (1) , 16-31
- https://doi.org/10.1046/j.1524-4733.2001.004001016.x
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Constraints on Antidepressant Prescribing and Principles of Cost-Effective Antidepressant UsePharmacoEconomics, 1997
- Depression in the communityInternational Clinical Psychopharmacology, 1997
- Modelling the Cost Effectiveness of Antidepressant Treatment in Primary CarePharmacoEconomics, 1995
- Cost Analysis of Paroxetine versus Imipramine in Major DepressionPharmacoEconomics, 1995
- A Markov Process Analysis Comparing the Cost Effectiveness of Maintenance Therapy with Citalopram versus Standard Therapy in Major DepressionPharmacoEconomics, 1995
- Assessing the Economic Value of a New AntidepressantPharmacoEconomics, 1995
- The cost of treatment dropout in depression A cost-benefit analysis of fluoxetine vs. tricyclicsJournal of Affective Disorders, 1994
- What Price Depression?The British Journal of Psychiatry, 1994
- Cost Utility of Maintenance Treatment of Recurrent Depression with Sertraline Versus Episodic Treatment with DothiepinPharmacoEconomics, 1994
- The costs of depressionInternational Clinical Psychopharmacology, 1993